Eupraxia Pharmaceuticals

EPRX

Market cap $423M

VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General Meeting of Shareholders (the “Meeting”) held on June 18, 2026.

VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026. Jefferies Global Healthcare Conference 1x1 Meetings: June 3rd and 4th Presentation Date & Time: June 3rd, 2026, at 5:30PM – 6:00PM ET Location: New York, NY Webcast registration link: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/8dAzVtF9jmoLFUYwXokBzq If you are interested in meeting with the Eupraxia team during the conference, please contact your Jefferies representative.

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2026. "The clinical data reported this quarter further reinforces the potential for EP-104GI to become an important new treatment for Eosinophilic Esophagitis (EoE),” said Dr. James A.

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue architecture (which is a measure of fibrosis) EoEHSS sub scores for inflammation demonstrated improvements in all reported cohorts at both 12 weeks (n=31) and 36 weeks (n=27) EoEHSS sub scores for tissue architecture (fibrosis) demonstrated improvements across most reported cohorts at 12 and 36 weeks The largest response in both the inflammatory and the architectural (fibrosis) sub scores was seen at the highest dose tested VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first release of sub score data from the Eosinophilic Esophagitis Histologic Scoring System (“EoEHSS”) in its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE").

EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS data reported by Eupraxia demonstrated a relationship between the number of injections of EP-104GI and the overall improvements in the EREFS findings A consistent response in both the inflammatory and fibrotic sub scores of EREFS was demonstrated for patients who received 20 injections. This also represents the number of injections being studied in the placebo-controlled Phase 2b portion of the RESOLVE trial VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”).

VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia's current CMO.

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company will present 4 abstracts at Digestive Disease Week (“DDW”) Annual meeting being held May 2-5, 2026 in Chicago, Illinois. Clinical data will be presented from the ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis (“EoE”).

ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.

William Blair on Monday initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products.

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise.